

02:00 - 02:30 pm
Explora la plataforma SOPHiA DDM™ que ofrece información: Pionera en datos de salud digitales descentralizados.
Gabriela Acosta,SOPHiA GENETICS, Sales Executive LATAM

02:30 - 03:00 pm
Navegando la complejidad del análisis genómico en cánceres hematológicos
Luna Rodriguez,SOPHiA GENETICS, Subject Matter Expert LATAM

03:00 - 03:30 pm
Experiencia de Uso de NGS en Hemato-oncología en el Sistema Público de Salud
Juan Galindo Valdés, BioquimicoLaboratorio Clínico, Hospital Del Salvador, Chile

03:30 – 04:00
De la muestra al resultado: potenciando la biopsia líquida como herramienta diagnóstica
Luna Rodriguez,SOPHiA GENETICS, Subject Matter Expert LATAM

04:00 – 06:00
Cocktails & Networking.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.